Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats

International Journal of Medical Sciences

Volumn 7, Issue 4, 2010, Pages 232-239

  Alsarra, Ibrahim A ^a,b   Ahmed, Mahrous O ^a   Alanazi, Fars K ^a   Eltahir, Kamal Eldin Hussein ^a   Alsheikh, Abdulmalik M ^b   Neau, Steven H ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Gastric ulcers; Histological examination; Hydroxypropyl cyclodextrin; Indomethacin; Piroxicam; cyclodextrin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; FIBRIN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLD STRESS; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; MALE; NEUROPIL; NONHUMAN; RAT; STOMACH PROTECTION; STOMACH ULCER;

EID: 77955543478     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.7.232     Document Type: Article

References (54)

1. Bulbena O, Escolar G, Navarro C, et al. Gastroprotective effect of zinc acexamate against damage induced by nonsteroidal anti- inflammatory drugs: A morphological study. Dig Dis Sci. 1993; 38: 730-39.
2. Caso JR, Leza JC, Menchén L. The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. Curr Mol Med. 2008; 8: 299-312.
3. Kleiman-Wexler RL, Adair CG, Ephgrave KS. Pharmacokinetics of naloxone: an insight into the locus of effect on stress-ulceration. J Pharmacol Exp Ther. 1989; 251: 435-8.
4. Savran B, Görgün CZ, Zengil H. Circadian reactivity rhythm of rat gastric mucosa to restraint-cold stress and indomethacin: Temporal variation in the protective effect of iloprost. Chronobio Int. 1997; 14: 575-583.
5. Waisman Y, Dinari G, Marcus H, et al. Naloxone is protective against indomethacin-induced intestinal ulceration in the rat. Gastroenterology. 1985; 89: 86-91.
6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature 1971; 231: 232-5.
7. Vane JR. Mechanism of nonsteroidal anti-inflammatory drugs. Am J Med. 1998; 104: 25-85.
8. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998; 41: 1591-602.
9. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995; 44: 1-10.
10. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol. 2006; 57: 113-24.
11. El-Bayer H, Steel L, Montcalm E, et al. The role of endogenous prostaglandins in the regulation of gastric secretion in rhesus monkeys. Prostaglandins. 1985; 30: 401-17.
12. Wallace JL, Whittle BJ, Boughton-Smith NK. Prostaglandin protection of rat colonic mucosa from damage induced by ethanol. Dig Dis Sci. 1985; 30: 866-76.
13. Ribeiro-Rama AC, Figueiredo IV, Veiga F, et al. Evaluation of gastric toxicity of indomethacin acid, salt form and complexed forms with hydroxypropyl-β-cyclodextrin on Wistar rats: Histopathologic analysis. Fund Clin Pharmacol. 2009; 23: 747-55.
14. Bhargava KP, Gupta MB, Tangri KK. Mechanism of ulcerogenic activity of indomethacin and oxyphenbutazone. Eur J Pharmacol. 1973; 22: 191-5.
15. Szejtli J. Cyclodextrin properties and applications. Drug Invest. 1990; 2: 11-21.
16. Uekama K, Irie T. New perspectives in cyclodextrin pharmaceutical applications: Cyclodextrin derivatives as new drug carriers. Drug Invest. 1990; 2: 22-8.
17. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997; 86: 147-62.
18. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Systems. 1987; 3: 1-40.
19. Lin SZ, Wouessidjewe D, Poelman MC, et al. Indomethacin and CDs complexes. Int J Pharm. 1991; 69: 211-9.
20. Iohara D, Hirayama F, Ishiguro T, et al. Preparation of amorphous indomethacin from aqueous 2,6-di-O-methyl- β-CD solution. Int J Pharm. 2008; 354: 70-6.
21. Lin SZ, Wouessidjewe D, Poelman MC, et al. In vivo evaluation of indomethacin/cyclodextrin complexes gastrointestinal tolerance and dermal antiiflammatory activity. Int J Pharm. 1994; 106: 63-7.
22. Jambhekar S, Casella R, Maher T. The physicochemical characteristics and bioavailability of indomethacin from β-CD, hydroxyethyl β-CD and HP-β-CD complexes. Int J Pharm. 2004; 270: 149-66.
23. Backensfeld T, Müller BW, Wiese M, et al. Effect of cyclodextrin derivatives on indomethacin stability in aqueous solution. Pharm Res. 1990; 7: 484-90.
24. Djedaini F, Lin SZ, Perly B, et al. High field nuclear magnetic resonance techniques for the investigation of a β-cyclodextrin:indomethacin inclusion complex. J Pharm Sci. 1990; 79: 643-6.
25. Redenti E, Szente L, Szejtli J. Cyclodextrin complexes of salts of acidic drugs: Thermodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci. 2001; 90: 979-86.
26. Goodman LS, Gilman A, Rall TW, et al. The pharmacological basis of therapeutics. Toronto, Canada: McGraw-Hill; 1992: 498-501.
27. Hobbs DC. Pharmacokinetics of piroxicam in man. Eur J Rheumatol Inflamm. 1983; 6: 46-55.
28. Jug M, Becirevic-Lacan M. Multicomponent complexes of piroxicam with cyclodextrins and HPMC. Drug Dev Ind Pharm. 2004; 30: 1051-60.
29. Jug M, Becirevic-Lacan M, Kwokal A, et al. Influence of cyclodextrin complexation on piroxicam gel formulations. Acta Pharma. 2005; 55: 223-36.
30. Xiliang G, Yu Y, Guoyan Z, et al. Study of inclusion interaction of piroxicam with β-CD derivatives. Spectrochimica Acta Part A Mol Biomol Spectrosc. 2003; 59: 3379-86.
31. Qing L, Hiroyuki T, Yukio K, et al. Characterization of the transdermal transport of flurbiprofen and indomethacin. J Control Rel. 2006; 110: 542-556.
32. Fujii M, Hori N, Shiozawa K, Wakabayashi K, Kawahara E, Matsumoto M. Effect of fatty acid esters on permeation of ketoprofen through hairless rat skin. Int J Pharm. 2000; 205: 117-125.
33. Cheong H-A, Choi H-K. Enhanced percutaneous absorption of piroxicam via salt formation with ethanolamines. Pharm Res. 2002; 19:1375-80.
34. Higuchi T, Connors KA. Phase solubility techniques. Adv. Anal. Chem. Instrum 1965; 4: 117-212.
35. Schmassmann A, Peskar BM, Selter C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro- intestinal ulcer models in rats. Br J Pharmacol. 1998; 123: 795-804.
36. Brzozowski T, Konturek PC, Konturek SJ, et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech. 2001; 1: 343-53.
37. Chandranath SI, Bastaki SM, Singh JA. A comparative study on the activity of lansoprazole, omeprazole and PD-136450 on acidified ethanol- and indomethacin-induced gastric lesions in the rat. Clin Exp Pharmacl Physiol. 2002; 29: 173-80.
38. Stroff T, Plate S, Ebrahim SJ, et al. Tachykinin-induced increase in gastric mucosal resistance: role of primary afferent neurons, CGRP, and NO. Am J Physiol. 1996; 271: G1017-27.
39. Peskar BM. Neural aspects of prostaglandin involvement in gastric mucosal defense. J Physiol Pharmacol. 2001; 52: 555-68.
40. Gretzer B, Ehrlich K, Maricic N, et al. Selective cyclo- oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol. 1998; 123: 927-35.
41. Peskar BM, Ehrlich K, Peskar BA. Interaction of cyclooxygenase- 2 inhibitors and salicylate in gastric mucosal damage. Eur J Pharmacol. 2002; 434: 65-70.
42. Wallace JL, Whittle BJR. Role of mucus in the repair of gastric epithelial damage in rat. Gastroenterology. 1985; 91: 611-30.
43. Rainsford KD. Relations between gastric irritancy/ ulcerogenicity and anti-oedemic activity of non-steroidal anti-inflammatory drugs. J Pharm Pharmacol. 1985; 37: 678-9.
44. Shoman ME, Abdel-Aziz M, Aly OM, et al. Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives. Eur J Med Chem. 2009; 44: 3068-76.
45. Morsy M, Ashour O, Amin E, et al. Gastroprotective effects of telmisartan on experimentally-induced gastric ulcers in rats. Pharmazie. 2009; 64: 590-4.
46. Tandon R, Khanna HD, Dorababu M, et al. Oxidative stress and antioxidants status in peptic ulcer and gastric carcinoma. Indian J Physiol Pharmacol. 2004; 48: 115-8.
47. Tanaka A, Hatazawa R, Takahira Y, et al. Preconditioning stress prevents cold restraint stress-induced gastric lesions in rats: roles of COX-1, COX-2, and PLA2. Dig Dis Sci. 2007; 52: 478-87.
48. Konturek PK, Brzozowski T, Konturek SJ, et al. Role of epidermal growth factor, prostaglandin, and sulfhydryls in stress-induced gastric lesions. Gastroenterology. 1990; 99: 1607-15.
49. Das D, Banerjee RK. Effect of stress on the antioxidant enzymes and gastric ulceration. Mol Cell Biochem. 1993; 125: 115-25.
50. Moody FG, Cheung LY. Stress ulcers: their pathogenesis, diagnosis, and treatment. Surg Clin North Am. 1976; 56: 1469-78.
51. Feliciano DV. Do perforated duodenal ulcers need an acid- decreasing surgical procedure now that omeprazole is available? Surg Clin North Am. 1992; 72: 369-80.
52. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999; 282: 1921-8.
53. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000; 59: 957-80.
54. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247-55.